Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
Key Highlights
- ➤Phio to present INTASYL® siRNA platform at Global Markets Virtual Forum October 8, 2026
- ➤CEO Robert Bitterman will discuss differentiated delivery approach and strategic direction
- ➤PH-762 Phase 1b trial evaluated cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma
- ➤Phio expects activities supporting PH-762’s next clinical-development phase completed during first quarter of 2027
Expert Statements
Robert Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals
“The Global Markets Virtual Forum offers a unique forum to highlight Phio's differentiated siRNA therapeutic platform, which is designed to enhance immune-cell function in solid tumors and has demonstrated a strong safety profile”
Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www.VirtualInvestorConference.com
King of Prussia, Pennsylvania--(Newsfile Corp. - October 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary INTASYL® siRNA gene-silencing platform, today announced that Robert Bitterman, President and Chief Executive Officer, will present Phio's INTASYL® siRNA therapeutic platform, its differentiated delivery approach, and the Company's strategic direction at The Global Markets Virtual Forum hosted by www.VirtualInvestorConferences.com (VIC) on October 8(th), 2026.
Get started
Create a free account to read the full story.